Hcv The Journey From Discovery To A Cure

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume II".

​Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".

"COVID-19 reminds us how acutely the virus can impact humanity. In fact, viruses existed long before the emergence of homo sapiens. In this book on the history of antiviral drug discovery, the human aspects are highlighted. In Chapter 1, the author regales us with several episodes where history was shaped by viruses causing smallpox, yellow fever, etc. The fascinating history of the first discovery of virus, tobacco mosaic virus, was also recounted. Chapters 2-5 covered four classes of viruses such as HIV, hepatitis viruses, influenza viruses and coronaviruses. Each chapter begins how the virus was discovered, followed by vaccine development, and then focuses on the discovery of small molecule antiviral drugs. For chemistry aficionados, the end of the book is replete with abundant of bibliography for further understanding of the minutia of the stories, followed by molecular structures of the antiviral drugs. This book is of interest to anyone who wants to know the science behind virus, vaccines and antiviral drugs. It is especially useful for healthcare professionals who are interested in knowing how viruses, vaccines and antiviral drugs are discovered"--

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic. New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. Covers the entire field of antiviral drug discovery and development Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2 Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.

Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development. The editors recruited epserts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years. Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable. Provides wide coverage of privileged scaffolds in new drug discovery Includes complex and diverse natural product scaffolds Covers applications to peptides and peptide-based drugs

While research teams are producing relevant and valid knowledge for health promotion, there is not yet a structured manual and distinct field of health promotion research. This timely "state-of-the-art" handbook contributes to the structuring of such a field of research. This collection of original contributions explores the major epistemological, methodological, and ethical challenges facing health promotion research. It brings together experts from different "research traditions" that coexist in the field. The handbook covers the existing knowledge production and sharing practices to delineate the "discipline" and its agenda for future research. Ultimately, it contributes to the creation of a global community of health promotion researchers. The handbook is organized by four types of practices (what people actually do) studied in health promotion; the practices of: Individuals and populations in relation to their health and its determinants Professionals who intervene to improve population health Policy-makers and institutions involved in the advocacy, design, and implementation of policies and programs Researchers and innovators (academic scholars and global agencies) through which investment in research and production of evidence-based guidelines are made. Global Handbook of Health Promotion Research, Vol. 1: Mapping Health Promotion Research is a highly relevant reference tool for researchers and graduate students in health promotion, public health, education and socio-health sciences; practitioners in health, medical, and social sectors; policy-makers; and health research administrators.

Conquering Hepatitis C and Surviving Treatment This book's whole focus is on killing the virus and making it through the necessary treatment journey. Both authors have followed this path. They reveal the latest in research findings on methods to improve treatment success and how to integrate those crucial results in the HCV treatment process. Nine others share their emotional response to learning of their infection, their decision to begin treatment, experiences while undergoing treatment, and what they are doing now. This book provides the necessary information and tools to follow in their footsteps with confidence. - Gives predictive pre-treatment indicators to success. - Shows steps to take to improve chances of success. - Provides proven methods for side effect management. - Reveals latest research findings with references. "Conquering Hepatitis C and Surviving Treatment should be required reading for people embarking on therapy, as well as for health care providers. It will give patients the tools they need to successfully complete treatment, and the stories from the people who have already gone down that path are motivating." ~Paul Schleinitz, MD, April 20, 2010, Medford, Oregon Companion Web Site: www.hcvshare.org

The burden of hepatitis C virus (HCV) infection on the public health care system continues to remain significant despite the remarkable progress made in HCV therapeutics in the recent past. There are now almost a dozen oral interferon-free direct-acting antivirals available for the treatment of hepatitis C virus infection. Despite advances in the treatment of HCV, therapeutic gaps remain that are yet to be fully explored. Researchers and scientists still strive to understand virus-host interactions to map the disease’s progression along with extrahepatic manifestations and virus invasion strategies impacting the host’s immune system. This book briefly discusses the biology of HCV infection, virus-host interactions, molecular epidemiology of the infection, and the full spectrum of immune responses to hepatitis C. It also provides in-depth information about HCV, clinical diagnostics, and therapeutic knowledge to all stakeholders involved in HCV screening, diagnosis, treatment, and management. Topics covered in the chapters include 1) HCV-host interactions leading to asymptomatic acute infection, 2) the progression of acute HCV infection to chronic disease and subsequent extrahepatic comorbidities, 3) Innate and adaptive immune responses in HCV infections, 4) Consensus-based Approaches for Hepatitis C Screening and Diagnosis, 5) advances in hepatitis C therapy and global management of HCV, and 6) the outcomes of Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. This book is a valuable addition to undergraduate and postgraduate hepatology students and physicians, clinicians, hepatologists, and health care officials involved in HCV clinical diagnosis and therapeutics.